ArticleNature communications2022
A strategy to assess spillover risk of bat SARS-related coronaviruses in Southeast Asia.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Major bat-borne zoonotic viral epidemics in Asia and Africa: A systematic review and meta-analysis.Veterinary medicine and science · 2022Pooled it
- Article
- Metagenomic insights into pathogen diversity and public health risk of Haemaphysalis longicornis in Gansu Province of China.PLoS neglected tropical diseases · 2026Article
- Assessing the Origin of the COVID19 Pandemic Is Still Important.FASEB bioAdvances · 2026Article
- COVID-19 vaccination induces cross-neutralisation of sarbecoviruses related to SARS-CoV-2.NPJ vaccines · 2026Article
- Reassessing Early COVID-19 Strategies in East Asia: Insights From Japan and Korea.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2026Review
- Addressing the zoonotic threat of merbecoviruses.Nature microbiology · 2026Review
- Cross-clade vaccination to overcome sarbecovirus or merbecovirus neutralization gaps.Cell reports · 2026Article
- Programmable antibody-based chimeric entry receptors for sarbecoviruses.Communications biology · 2026Article
- Assessing Evidence to Guide Primary Prevention of Pathogen X.Emerging infectious diseases · 2026Article
- Article
- Viral Risks at the Human-Bat Interface: Household Bat Guano Farming in Rural Cambodia.Pathogens (Basel, Switzerland) · 2026Article
- Broad beta-CoV immunity and transmission blockade by a single-dose live-attenuated vaccine with atypical codon usage.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Strengthening preparedness and response to emerging henipavirus diversity.Frontiers in cellular and infection microbiology · 2026Review
- Emerging Respiratory Virus Threats from Influenza D and Canine Coronavirus HuPn-2018.Emerging infectious diseases · 2026Review
- Human-animal interfaces and zoonotic disease risks in China: a review of contact behaviors and risk communication.Science in One Health · 2026Review
- Viral emergence and pandemic preparedness in a One Health framework.Nature reviews. Microbiology · 2026Review
- Upscaling effects on infectious disease emergence risk emphasize the need for local planning in primary prevention within biodiversity hotspots.Scientific reports · 2025Article
- Global sampling decline erodes science potential of natural history collections.Nature communications · 2025Article
- Dual-Site Inhibition of SARS-CoV-2 RNA-Dependent RNA Polymerase by Small Molecules Able to Block Viral Replication Identified through a Computer-Aided Drug Discovery Approach.ACS infectious diseases · 2025Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Update of
Authors and funding
9 authors.
Funding
Abstract
Emerging diseases caused by coronaviruses of likely bat origin (e.g., SARS, MERS, SADS, COVID-19) have disrupted global health and economies for two decades. Evidence suggests that some bat SARS-related coronaviruses (SARSr-CoVs) could infect people directly, and that their spillover is more frequent than previously recognized. Each zoonotic spillover of a novel virus represents an opportunity for evolutionary adaptation and further spread; therefore, quantifying the extent of this spillover may help target prevention programs. We derive current range distributions for known bat SARSr-CoV hosts and quantify their overlap with human populations. We then use probabilistic risk assessment and data on human-bat contact, human viral seroprevalence, and antibody duration to estimate that a median of 66,280 people (95% CI: 65,351-67,131) are infected with SARSr-CoVs annually in Southeast Asia. These data on the geography and scale of spillover can be used to target surveillance and prevention programs for potential future bat-CoV emergence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.